- Home
- EIC vs FHTX Comparison
EIC vs FHTX Comparison
Compare EIC & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EIC | FHTX |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.8M | 247.1M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | EIC | FHTX |
|---|---|---|
| Price | $11.07 | $4.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $14.00 | $11.50 |
| AVG Volume (30 Days) | ★ 287.0K | 158.2K |
| Earning Date | 11-13-2025 | 11-05-2025 |
| Dividend Yield | ★ 14.02% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $59,262,402.00 | $24,518,000.00 |
| Revenue This Year | $37.84 | $47.50 |
| Revenue Next Year | $23.33 | N/A |
| P/E Ratio | $9.79 | ★ N/A |
| Revenue Growth | ★ 44.30 | N/A |
| 52 Week Low | $10.81 | $2.95 |
| 52 Week High | $16.39 | $6.79 |
Technical Indicators
Market Signals| Indicator | EIC | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 32.64 | 63.06 |
| Support Level | $10.90 | $4.21 |
| Resistance Level | $11.44 | $4.59 |
| Average True Range (ATR) | 0.21 | 0.29 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 29.11 | 78.50 |
Price Performance
Historical ComparisonAbout EIC Eagle Point Income Company Inc.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.